Qube Research & Technologies (QRT)’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-277,168	Closed	-$854K	–	3143
2023 Q1	$854K	Buy	277,168 +239,160	+629%	+$1.43M	﹤0.01%	1356
2022 Q4	$201K	Buy	38,008 +13,916	+58%	+$63.6K	﹤0.01%	1820
2022 Q3	$85K	Sell	24,092 -3,295	-12%	-$10.9K	﹤0.01%	2020
2022 Q2	$71K	Buy	+27,387	New	+$76.1K	﹤0.01%	2052
2020 Q4	–	Sell	-10,309	Closed	-$91K	–	2280
2020 Q3	$91K	Buy	+10,309	New	+$117K	﹤0.01%	1504

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Qube Research & Technologies (QRT)'s PSTX Position: Q2 2023 in Review

Qube Research & Technologies (QRT) sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2023, closing a stake of 277,168 shares — an estimated $854K sold.

Qube Research & Technologies (QRT) first reported a position in PSTX in Q3 2020 and held it in 5 quarters. The position peaked at $854K in Q1 2023. 94 funds tracked by Wall St. Rank hold PSTX as of Q2 2023.

Qube Research & Technologies (QRT) reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 277,168 Poseida Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $854K.
Qube Research & Technologies (QRT) first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
Qube Research & Technologies (QRT)'s Poseida Therapeutics, Inc. Common Stock position peaked at $854K in Q1 2023.
94 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2023, filed 14 Aug 2023.